Author: Qiu, Yingshan; Lam, Jenny K. W.; Leung, Susan W. S.; Liang, Wanling
Title: Delivery of RNAi Therapeutics to the Airways—From Bench to Bedside Document date: 2016_9_20
ID: 04pp3lv0_28
Snippet: Lung cancer is a leading cause of cancer death in the world. The mainstay of treatment is chemotherapy, which is indicated for around 70% of newly diagnosed patients with local and advanced metastatic disease [93] . Other treatment options include surgery and radiotherapy [94] . Angiogenesis inhibitors [95] and epidermal growth factor receptor (EGFR) inhibitors [96, 97] are new medications licensed for the treatment of lung cancer. Despite variou.....
Document: Lung cancer is a leading cause of cancer death in the world. The mainstay of treatment is chemotherapy, which is indicated for around 70% of newly diagnosed patients with local and advanced metastatic disease [93] . Other treatment options include surgery and radiotherapy [94] . Angiogenesis inhibitors [95] and epidermal growth factor receptor (EGFR) inhibitors [96, 97] are new medications licensed for the treatment of lung cancer. Despite various treatment options, the prognosis of lung cancer is poor. The major problems of chemotherapy are toxicity, lack of specificity and drug resistance [98] . In recent years, pulmonary delivery of RNAi molecules is being explored as a new treatment for lung cancer [99] . Genes that are associated with tumor cell growth and drug resistance are potential targets. Table 2 summarizes some recent in vivo studies of pulmonary RNAi delivery for lung cancer treatment.
Search related documents:
Co phrase search for related documents- advanced local metastatic disease and lung cancer treatment: 1
- advanced local metastatic disease and metastatic disease: 1, 2
- angiogenesis inhibitor and cell growth: 1
- angiogenesis inhibitor and growth factor: 1, 2
- angiogenesis inhibitor and growth factor receptor: 1
- angiogenesis inhibitor and potential target: 1
- cancer death and cell growth: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- cancer death and drug resistance: 1, 2, 3, 4, 5, 6, 7, 8, 9
- cancer death and growth factor: 1, 2, 3, 4, 5, 6, 7, 8
- cancer death and growth factor receptor: 1, 2, 3, 4
- cancer death and leading cause: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- cancer death and Lung cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- cancer death and lung cancer prognosis: 1, 2
- cancer death and lung cancer treatment: 1, 2, 3, 4, 5, 6, 7
- cancer death and major problem: 1, 2
- cancer death and metastatic disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- cancer death and new treatment: 1, 2, 3, 4
- cancer death and potential target: 1, 2, 3, 4, 5, 6
- cancer death and recent year: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date